Trefoil Therapeutics

About Trefoil Therapeutics

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

What does Trefoil Therapeutics do?

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Where is Trefoil Therapeutics located?

Trefoil Therapeutics is based in San Diego, United States.

When was Trefoil Therapeutics founded?

Trefoil Therapeutics was founded in 2013.

How much funding has Trefoil Therapeutics raised?

Trefoil Therapeutics has raised 12000000.

Location
San Diego, United States
Founded
2013
Funding
12000000
Employees
11 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Start Searching

Trefoil Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

trefoiltherapeutics.com1K+
cb
Crunchbase
Founded 2013 – San Diego, United States

Funding

$

Estimated Funding

$10M+

Team (10+)

No team information available.

Company Description

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.